Patents by Inventor Kay-Gunnar Stubenrauch
Kay-Gunnar Stubenrauch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240219381Abstract: Herein is reported a method for determining the concentration of a therapeutic antibody in a tissue of an experimental animal to whom the therapeutic antibody had been administered, wherein the interference from residual blood in a tissue sample of the experimental animal, which is used for determining the concentration of the therapeutic antibody in said tissue, is reduced, wherein the concentration of the therapeutic antibody in the tissue of the experimental animal is calculated with the following formula: C tmAb , t ? i ? s ? s ? u ? e = C t ? mAb , tissue , det . C tissue , sample - C refmAb , tissue , det . C tissue , sample C refmAb , plasma , det . * C tmAb , plasma , det . wherein CtmAb,tissue,det.=obtained by determining the concentration of the therapeutic antibody in the tissue sample of the experimental animal, CtmAb,plasma,det.Type: ApplicationFiled: February 2, 2024Publication date: July 4, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Martin Schaefer, Sylvia Rottach, Gregor Jordan, Kay-Gunnar Stubenrauch, Roland Staack, Kevin Brady
-
Patent number: 11970550Abstract: The invention provides anti-variant Fc-region antibodies which specifically bind to an antibody that has the mutation P329G or the mutations P329G/L234A/L235A or the mutations 1253A/H310A/H435A in the Fc-region, and methods of using the same.Type: GrantFiled: December 7, 2020Date of Patent: April 30, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Frank Kowalewsky, Mirko Ritter, Kay-Gunnar Stubenrauch, Uwe Wessels
-
Patent number: 11913945Abstract: Herein is reported a method for determining the concentration of a therapeutic antibody in a tissue of an experimental animal to whom the therapeutic antibody had been administered, wherein the interference from residual blood in a tissue sample of the experimental animal, which is used for determining the concentration of the therapeutic antibody in said tissue, is reduced by applying an inert reference antibody that does not penetrate into said tissue, whereby the inert reference antibody is administered 2 to 10 minutes prior to obtaining the tissue and blood sample.Type: GrantFiled: December 29, 2020Date of Patent: February 27, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Martin Schaefer, Sylvia Rottach, Gregor Jordan, Kay-Gunnar Stubenrauch, Roland Staack, Kevin Brady
-
Publication number: 20230390338Abstract: The present invention generally relates to antigen binding receptors capable of specific binding to mutated Fc domains with reduced Fc receptor binding and T cells expressing these antigen binding receptors. More precisely, the present invention relates to T cells, transfected/transduced with an antigen binding receptor which is recruited by specifically binding to/interacting with the mutated Fc domain of therapeutic antibodies. Furthermore, the invention relates to a kit comprising the T cells of the invention and/or nucleic acid molecules, vectors expressing antigen binding receptors of the present invention and (a) tumor targeting antibody/antibodies comprising a mutated Fc domain.Type: ApplicationFiled: May 4, 2023Publication date: December 7, 2023Inventors: Kay-Gunnar STUBENRAUCH, Ekkehard MOESSNER, Christian KLEIN, Diana DAROWSKI
-
Publication number: 20230212277Abstract: The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: December 23, 2022Publication date: July 6, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Harald Duerr, Frank Herting, Christian Klein, Joerg Thomas Regula, Matthias Rueth, Kay-Gunnar Stubenrauch
-
Patent number: 11679127Abstract: The present invention generally relates to antigen binding receptors capable of specific binding to mutated Fc domains with reduced Fc receptor binding and T cells expressing these antigen binding receptors. More precisely, the present invention relates to T cells, transfected/transduced with an antigen binding receptor which is recruited by specifically binding to/interacting with the mutated Fc domain of therapeutic antibodies. Furthermore, the invention relates to a kit comprising the T cells of the invention and/or nucleic acid molecules, vectors expressing antigen binding receptors of the present invention and (a) tumor targeting antibody/antibodies comprising a mutated Fc domain.Type: GrantFiled: September 19, 2019Date of Patent: June 20, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Kay-Gunnar Stubenrauch, Ekkehard Moessner, Christian Klein, Diana Darowski
-
Publication number: 20230131782Abstract: Herein is reported a method for determining the epitope of an antibody specifically binding to a therapeutic antibody comprising the steps of a) incubating a sample, which comprises serum and the antibody specifically binding to a therapeutic antibody, separately with i) at least a Fab fragment of the therapeutic antibody, and ii) at least a Fab fragments of the therapeutic antibody in which the HVRs forming a paratope have been replaced with germline sequences, and detecting the binding or non-binding of the antibody specifically binding to a therapeutic antibody to the at least a Fab fragment in any of i) to ii), and b) determining the epitope of the antibody specifically binding to a therapeutic antibody to be in the at least one HVR that has been replaced in ii) if binding is detected in i) and non-binding is detected in ii).Type: ApplicationFiled: June 30, 2022Publication date: April 27, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Roland BECKMANN, Ekkehard MOESSNER, Kay-Gunnar STUBENRAUCH
-
Publication number: 20230119537Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.Type: ApplicationFiled: June 17, 2022Publication date: April 20, 2023Inventors: Peter BRUENKER, Rebecca CROASDALE-WOOD, Christian KLEIN, Juergen Michael SCHANZER, Kay-Gunnar STUBENRAUCH, Pablo UMANA, Martina GEIGER, Eric SULLIVAN, Jigar PATEL
-
Publication number: 20230111088Abstract: The invention provides a method for the immunological determination of an antibody against a drug antibody in a sample using a double antigen bridging immunoassay comprising a capture drug antibody and a tracer drug antibody, characterized in that the capture drug antibody is a mixture of said drug antibody conjugated to the solid phase at at least two different antibody sites and the tracer drug antibody is a mixture of said drug antibody conjugated to the detectable label at at least two different antibody sites.Type: ApplicationFiled: December 8, 2022Publication date: April 13, 2023Inventors: Wolfgang Hoesel, Kay-Gunnar Stubenrauch, Rudolf Vogel
-
Patent number: 11561229Abstract: Herein is reported a method for the determination of the amount of a bivalent antibody in a serum or plasma sample obtained from a non-human experimental animal, whereby the antibody comprises one or more mutations in the Fc-region compared to the corresponding wild-type Fc-region that has a sequence of SEQ ID NO: 01, 02, or 03, wherein the method comprises the following steps a) immobilizing a non-antibody polypeptide to which more than one copy of the antigen of the antibody is covalently conjugated on a solid surface, b) incubating the immobilized antigen with the sample to form an immobilized antigen-antibody complex, c) incubating the immobilized antigen-antibody complex with the antigen conjugated to a detectable label to form an immobilized ternary complex, and d) determining the amount of the antibody by determining the amount of the detectable label in the immobilized ternary complex.Type: GrantFiled: May 24, 2018Date of Patent: January 24, 2023Assignee: Hoffmann-La Roche Inc.Inventor: Kay-Gunnar Stubenrauch
-
Publication number: 20220357340Abstract: Herein is reported a method for determining the concentration of a therapeutic antibody in a tissue of an experimental animal to whom the therapeutic antibody had been administered, wherein the interference from residual blood in a tissue sample of the experimental animal, which is used for determining the concentration of the therapeutic antibody in said tissue, is reduced, wherein the concentration of the therapeutic antibody in the tissue of the experimental animal is calculated with the following formula: C tmAb , tissue = C t ? m ? A ? b , tissue , det . C t ? i ? s ? sue , sample - C r ? e ? f ? m ? A ? b , tissue , det . C t ? i ? s ? sue , sample C r ? e ? f ? m ? A ? b , plasma . det . * C t ? m ? A ? b , plasma , det . wherein CtmAb,tissue,det.=obtained by determining the concentration of the therapeutic antibody in the tissue sample of the experimental animal, CtmAb,plasma,det.Type: ApplicationFiled: June 14, 2022Publication date: November 10, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Kevin BRADY, Gregor JORDAN, Sylvia ROTTACH, Martin SCHAEFER, Roland STAACK, Kay-Gunnar STUBENRAUCH
-
Publication number: 20220275087Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.Type: ApplicationFiled: December 2, 2021Publication date: September 1, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Peter BRUENKER, Rebecca CROASDALE-WOOD, Christian KLEIN, Juergen Michael SCHANZER, Kay-Gunnar STUBENRAUCH, Pablo UMANA, Martina GEIGER, Eric SULLIVAN, Jigar PATEL
-
Patent number: 11340234Abstract: Herein is reported an anti-drug antibody immunoassay for the determination of the presence of an anti-drug antibody against an effector function suppressed human or humanized drug antibody in a sample comprising the incubation of a sample comprising mammalian blood serum with full length human Fcgamma receptor I or an Fc-region binding fragment thereof so that a complex between the anti-drug antibody against the effector function suppressed human or humanized drug antibody present in the sample and the human Fcgamma receptor I or the Fc-region binding fragment thereof forms, whereby the full length human Fcgamma receptor I or the Fc-region binding fragment thereof is conjugated to a detectable label, and the determination of the formed complex by the detectable label.Type: GrantFiled: May 5, 2017Date of Patent: May 24, 2022Inventors: Pablo Umana, Uwe Wessels, Kay-Gunnar Stubenrauch
-
Patent number: 11313864Abstract: The present invention relates to in vitro methods for determining the presence or absence of an anti-drug antibody (ADA) or drug/ADA immunecomplexes in a minipig sample. The invention further relates to antibodies specifically binding to minipig IgG that are applicable in the methods of the invention.Type: GrantFiled: February 6, 2020Date of Patent: April 26, 2022Assignee: Hoffmann-La Roche Inc.Inventors: Janis Brockhaus, Astrid Reiser, Mirko Ritter, Kay-Gunnar Stubenrauch, Rudolf Vogel, Markus Zadak
-
Patent number: 11242390Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.Type: GrantFiled: September 21, 2018Date of Patent: February 8, 2022Assignee: Hoffmann-La Roche Inc.Inventors: Peter Bruenker, Rebecca Croasdale-Wood, Christian Klein, Juergen Michael Schanzer, Kay-Gunnar Stubenrauch, Pablo Umana, Martina Geiger, Eric Sullivan, Jigar Patel
-
Publication number: 20210364504Abstract: Herein is reported a method for determining the concentration of a therapeutic antibody in a tissue of an experimental animal to whom the therapeutic antibody had been administered, wherein the interference from residual blood in a tissue sample of the experimental animal, which is used for determining the concentration of the therapeutic antibody in said tissue, is reduced, wherein the concentration of the therapeutic antibody in the tissue of the experimental animal is calculated with the following formula: C tmAb , tissue = C tmAb , tissue , det . C tissue , sample - C refmAb , tissue , det . C tissue , sample C refmAb , plasma . det . * C tmAb , plasma , det . wherein CtmAb,tissue,det.=obtained by determining the concentration of the therapeutic antibody in the tissue sample of the experimental animal, CtmAb,plasma,det.Type: ApplicationFiled: December 29, 2020Publication date: November 25, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Martin Schaefer, Sylvia Rottach, Gregor Jordan, Kay-Gunnar Stubenrauch, Roland Staack, Kevin Brady
-
Publication number: 20210163626Abstract: The invention provides anti-variant Fc-region antibodies which specifically bind to an antibody that has the mutation P329G or the mutations P329G/L234A/L235A or the mutations 1253A/H310A/H435A in the Fc-region, and methods of using the same.Type: ApplicationFiled: December 7, 2020Publication date: June 3, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Frank Kowalewsky, Mirko Ritter, Kay-Gunnar Stubenrauch, Uwe Wessels
-
Publication number: 20210095013Abstract: The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: May 5, 2020Publication date: April 1, 2021Applicant: Roche Glycart AGInventors: Harald Duerr, Frank Herting, Christian Klein, Joerg Thomas Regula, Matthias Rueth, Kay-Gunnar Stubenrauch
-
Publication number: 20210055304Abstract: Herein is reported a method for the detection of free antigen of a multispecific antibody in a sample, whereby the antigen to be detected can be specifically bound by a first binding site of the multispecific antibody, comprising the step of incubating a sample comprising free antigen and multispecific antibody with an anti-idiotypic antibody, which specifically binds to a second binding specificity of the bispecific antibody, which is different from the first binding specificity, whereby the anti-idiotypic antibody is bound to a solid phase.Type: ApplicationFiled: July 31, 2020Publication date: February 25, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Kay-Gunnar STUBENRAUCH, Uwe WESSELS
-
Patent number: 10899845Abstract: The invention provides anti-variant Fc-region antibodies which specifically bind to an antibody that has the mutation P329G or the mutations P329G/L234A/L235A or the mutations I253A/H310A/H435A in the Fc-region, and methods of using the same.Type: GrantFiled: April 25, 2018Date of Patent: January 26, 2021Assignee: Hoffmann-La Roche Inc.Inventors: Frank Kowalewsky, Mirko Ritter, Kay-Gunnar Stubenrauch, Uwe Wessels